




版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领
文档简介
DiabetesMellitus2025/2/281BeijingXuanwuHospitalDiabetesMellitusdefinitiontypessymptomsdiagnosisLaboratoryfindingstreatmentcomplications2025/2/282BeijingXuanwuHospitalDefinition-WHO(4/2000)Thetermdiabetesmellitusdescribesametabolicdisorderofmultipleaetiologycharacterizedbychronichyperglycaemiawithdisturbancesofcarbohydrate,fatandproteinmetabolismresultingfromdefectsininsulinsecretion,insulinaction,orboth2025/2/283BeijingXuanwuHospitalDefinitionAmetabolicconditioncharacterisedbyhighplasmaglucoselevelsandchronicvascularcomplicationsAvasculardiseaseaffectingsmallandlargearterieswithcoexistentmetabolicdisturbanceparticularlyhighplasmaglucoselevels2025/2/284BeijingXuanwuHospitalDiabetesMellitusdefinitiontypessymptomsdiagnosisLaboratoryfindingstreatmentcomplications2025/2/285BeijingXuanwuHospitalAetiologicalClassificationofDisordersofGlycaemiaType1
(beta–celldestruction,usuallyleadingtoabsoluteinsulindeficiency):Autoimmune:IdiopathicType2
(mayrangefrompredominantlyinsulinresistancewithrelativeinsulindeficiencytoapredominantlysecretorydefectwithorwithoutinsulinresistance)Otherspecifictypes
Geneticdefectsofbeta–cellfunction GeneticdefectsininsulinactionDiseasesoftheexocrinepancreasEndocrinopathies Drug–orchemical–inducedInfections Uncommonformsofimmune–mediateddiabetes OthergeneticsyndromessometimesassociatedwithdiabetesGestationaldiabetes2025/2/286BeijingXuanwuHospitalType1diabetesPreviouslyknownasIDDM(Insulindependentdiabetes)Ketosisprone:Usuallydiagnosedinyoungeragegroup(<30years)(Peakincidence11-13yr)Prevalencehighlyvariablebutapproximately0.20%withanincidenceof15-20per100000populationagedlessthan21Seasonalvariation-withlowestrateinspringandsummer2025/2/287BeijingXuanwuHospitalType1diabetesmellitusImmune-mediatedtype1diabetesacuteLADAlatentautoimmunediabetesinadults
Idiopathictype1diabetesmellitus2025/2/288BeijingXuanwuHospitalType1diabetesmellitusGeneticsEnvironmentalfactorVirusesChemicalagentsAutoimmune
Auto-antibodies:isletcellcytoplasmantibody(ICCA)isletcellsurfaceantibody(ICSA)glutamicaciddecarboxylaseantibodyGADA(64KD)Insulinantibody(IAA)
2025/2/289BeijingXuanwuHospitalType1diabetesThispresentationistheendpointofrecentandcontinuingbetacellfunctionresultinginneartotallossofInsulinproductionHyperglycaemiaitselfbegetsfurtherbetacelldestructionastreatmentwithinsulinoftenresultsina“honeymoon〞periodwhenthepatientcanoftenmanagewithoutinsulin2025/2/2810BeijingXuanwuHospitalType1diabetesmellitususuallyautoimmunedestructionof
insulin-producingpancreaticisletcells
overmonthsabsoluteinsulindeficiencyrapidpresentationwith
thirst,polyuria,weightloss,blurredvision
thrush,lethargy,dizziness.nausea,vomiting,abdominalcramps,andsuperficialinfectionusuallythinandketoticatpresentationAuto-antibodiesidentified:antiisletcell(ICCA.ICSA),antiGAD(64KD),antiInsulin(IAA)2025/2/2811BeijingXuanwuHospitalAprogressivemetabolicdisorder
characterisedby:
InsulinresistanceType2diabetes
-celldysfunction2025/2/2812BeijingXuanwuHospitalType2diabetesPreviouslyknownasNIDDMNonketosisprone:,diagnosis>30years1in1000populationasnewcaseseachyearInsidiouspresentationwithsymptomsofpolyuria,polydipsia,lethargy,weightloss,nausea,vomiting,abdominalcramps,blurredvisionandsuperficialinfection.OftendiscoveredatroutinemedicalThispresentationistheendpointofthegraduallossofbetacellfunctioninthesettingofInsulinresistanceStrong(90-100%)concordanceinTwinsReavan’ssyndromeorSyndromeX Insulinresistance2025/2/2813BeijingXuanwuHospitalType2diabetesUnderlyinginsulinresistancegeneticandethnicityObesityBMIWHRinactivity/lowphysicalfitnessintrauterine&childhoodfactorssmoking&drugsImpairedinsulinsecretionInsulinsecretionworsenswithtimepost-receptor
cellularmechanismsmechanism
unclearb-cell
exhaustion2025/2/2814BeijingXuanwuHospitalType2diabetesPrandialglucoseFastingglucoseInsulinresistanceInsulinsecretionPlasmaglucoseß-cell126mg/dLyears2025/2/2815BeijingXuanwuHospitalPancreatic
-cell
InsulinresistanceLiverHYPERGLYCAEMIAIslet
-celldegranulation
ReducedinsulincontentMuscle(PKC
Adiposetissue
Decreasedglucosetransport
&activity(expression)ofGLUT-4IncreasedlipolysisElevatedplasmaNEFA+-LowplasmainsulinIncreasedglucoseoutputElevatedTNF
Insulinresistanceand
-celldysfunctionproducehyperglycaemiaintype2diabetes2025/2/2816BeijingXuanwuHospitalTissueResponsestoInsulin
ResistanceorFailure
LIVERa.increasedglycogenhydrolysistoglucoseb.increasedgluconeogenesis.c.increasedtriacylglycerolhydrolysisandconversionofglyceroltoglucosed.increasedconversionofFAandproteintoketones(AcAcandBHB)e.increasedproteinandaminoacidcatabolismf.increasedproductionofurea2025/2/2817BeijingXuanwuHospitalMUSCLE
a.serumglucoseispoorlytakenupbymuscle(decreaseGLUTactivity)b.saturationofhexokinaseactivity,inabilitytoretaincellulargluasglu-6-PO4c.increasedLPLactivityandincreasedFAproductiond.increasedb-oxidation,butTCAisoverwhelmedbecauseATPishighalreadyee.increasedbreakdownofmuscleandserumproteinintoaminoacidsf.increasedtransferofNontoALA/GLNandsentbacktoliver2025/2/2818BeijingXuanwuHospitalADIPOSEa.increasedLPLandHSLsendmorefreeFAintobloodstreamb.glucosecannotbetakenintocellviaGLUT4forglycogensynthesisc.activeHSLmeansTAGsarenotbeingmadeandstored2025/2/2819BeijingXuanwuHospitalInsulinresistanceandinsulin
hypersecretionprecedetype2diabetesInsulinInsulinMacrovascularsensitivitysecretiondisease30%50%50%50%70–100%40%70%150%10%100%100%Type2diabetesIGTImpairedglucosemetabolismNormalglucosemetabolism2025/2/2820BeijingXuanwuHospitalClinicalReavansSyndromeInsulinresistanceHypertensionDyslipidaemia(increaseLDL,decreasedHDL)ObesityOtherfactors:hyperfibrinogenemia,hyperuricaemia,propensitytomicrovasculardiseases“Metabolicsyndrome〞inmostcasesoftype2diabetes2025/2/2821BeijingXuanwuHospitalabdominalobesityhighbloodpressureHDLcholesterol
VLDLtriglyceride
smalldenseLDL
hyperinsulinaemiaglucoseintolerancediabeteshyperuricaemiaPAI-1
fibrinogen
factorVII
microalbuminuriainsulinresistanceSyndromeofinsulinresistanceAKA Reaven’ssyndrome,syndromeX metabolicsyndrome2025/2/2822BeijingXuanwuHospitalType1diabetestypicalonset<30yearscanstartatanyagesuddenonsetseveresymptomsrecentweightlossusuallythinspontaneousketosisabsentC-peptidemarkersofautoimmunityType2diabetestypicalonset>20yearscanstartatanyagegradualonsetmaybenosymptomsoftennoweightlossusuallyobesenotketoticdetectableC-peptidenoautoimmunemarkers2025/2/2823BeijingXuanwuHospitalDiabetesinpregnancyco-existentornewlydiagnosedlifelongdiabetestype1type2(especiallyinSouthAsianwomen)otherspecifictypesofdiabetesgestationaldiabetes2025/2/2824BeijingXuanwuHospitalOthertypesofDiabetesGeneticdefectsofbeta–cellfunctionChr’me20,HNF4_(MODY1)Chr’me7,glucokinase(MODY2)Chr’me12,HNF1_(MODY3)Chr’me13,IPF–1(MODY4)MitochondrialDNA3243mutationGeneticdefectsininsulinactionTypeAinsulinresistanceLeprechaunismRabson–MendenhallsyndromeLipoatrophicdiabetes&OthersDiseasesoftheexocrine-pancreasFibrocalculouspancreatopathyPancreatitisTrauma/pancreatectomyNeoplasiaCysticfibrosisHaemochromatosis&OthersEndocrinopathiesCushing’ssyndromeAcromegalyPhaeochromocytomaGlucagonomaHyperthyroidismSomatostatinoma&Others
2025/2/2825BeijingXuanwuHospitalTypes-continuedInfectionsCongenitalrubellaCytomegalovirusOthers
Uncommonformsofimmune–mediateddiabetesInsulinautoimmunesyndrome(antibodiestoinsulin)Anti–insulinreceptorantibodies“StiffMan〞syndromeOthersDrug–orChemical–inducedDiabetes
NicotinicacidGlucocorticoidsThyroidhormoneAlpha–adrenergicagonistsBeta–adrenergicagonistsThiazidesDilantinPentamidineVacorInterferon–alphatherapyOthers2025/2/2826BeijingXuanwuHospitalPathophysiologyBecauseglucoseisnotgettingintocells,metabolismchangesCatabolismoffatsandproteinsinsteadofcarbohydratesLeadstoincreasedfattyacidsandketoacidsKetoacidosisresultsinloweringofpHDiabeticcomaDecompensatedmetabolicacidosisanddeath2025/2/2827BeijingXuanwuHospitalDiabetesMellitusdefinitiontypessymptoms
diagnosisLaboratoryfindingstreatmentcomplications2025/2/2828BeijingXuanwuHospitalSymptomsofdiabetesduetohyperglycaemiaHyperglycemiaDehydrationExcessivethirstandurinationExcessivehungerGlycosuria(gluspillsintourine:>180mg/dl)2025/2/2829BeijingXuanwuHospitalSymptomsofdiabetesduetohyperglycaemiaplasmaglucose
>renalthresholdabout12mmol/Lglucoseinurine
osmoticdiuresisurinevolumethirstgenitalthrushweightlosshyperglycaemiatiredness2025/2/2830BeijingXuanwuHospitalSymptomsofdiabetesduetohyperglycaemiahyperglycaemiaswellingoflens blurredvisioncerebraleffects lightheadedness malaise mentalchanges2025/2/2831BeijingXuanwuHospitalDiabetesMellitusdefinitiontypessymptomsdiagnosisLaboratoryfindingstreatmentcomplications2025/2/2832BeijingXuanwuHospitalADAdiagnosticcriteria(1997)Symptomsofdiabetes&acasualglucoseconcentrationmorethanorequalto200mg/dl(11.1mmol/l);Casualisdefinedasanytimeofdaywithoutregardstotimesincelastmeal.Theclassicsymptomsofdiabetesincludepolyuria,polydipsiaandunexplainedweightloss orFPGmorethanorequalto126mg/dl(7.0mmol/l).Fastingisdefinedasnocaloricintakeforatleast8hours or2hourPGmorethanorequalto200mg/dl(11.1mmol/l)duringanOGTT.ThetestshouldbeperformedasdescribedbyWHO,usingaglucoseloadcontainingtheequivalentof75gglucosedissolvedinwater2025/2/2833BeijingXuanwuHospitalWHOdiagnosticcriteria
wholeblood plasmaDiabetesmellitus
(fasting) >6.1mmol/l >7.0mmol/l2hourpostglucoseload >10.0mmol/l >11.1mmol/lIGT
(fasting) <6.1mmol/l <7.0mmol/l & &2hrpostglucoseload >6.7mmol/l >7.8mmol/lIFG
(fasting) >5.6mmol/l >6.1mmol/l &<6.1mmol/l &<7.0mmol/l2hrpostglucoseload ><6.7mmol/l <7.8mmol/lIGHimpairedglucosehomeostasis2025/2/2834BeijingXuanwuHospitalChangesfromOldcriteriaTheclass“ImpairedGlucoseTolerance〞isnowclassifiedasastageofimpairedglucoseregulation,sinceitcanbeobservedinanyhyperglycaemicdisorder,andisitselfnotdiabetes.ClinicalstageofImpairedFastingGlycaemiahasbeenintroducedtoclassifyindividualswhohavefastingglucosevaluesabovethenormalrange,butbelowthosediagnosticofdiabetes.GestationalDiabetesisretainedbutnowencompassesthegroupsformerlyclassifiedasGestationalImpairedGlucoseTolerance(GIGT)andGestationalDiabetesMellitus(GDM).2025/2/2835BeijingXuanwuHospitalDiagnosisofdiabetessymptoms+elevatedbloodglucoselevelORelevatedbloodglucoselevelsontwooccasions2025/2/2836BeijingXuanwuHospitalDifferentialDiagnosisHyperglycemiasecondarytoothercausesNondiabeticglycosuria2025/2/2837BeijingXuanwuHospitalDiabetesMellitusdefinitiontypessymptomsdiagnosisLaboratoryfindingstreatmentcomplications2025/2/2838BeijingXuanwuHospitalFPG:FastingPlasmaGlucoseCPG:CasualPlasmaGlucose(non-fasting)OGTT:OralGlucoseToleranceTest(75g)HemoglobinA1c(glycatedhemoglobin,glycosylatedhemoglobin)IndicatesaverageBGlevelsoverapprox.3months.%oftotalHgbattachedtoglucoseNormal:4-6%(DM:>8%)2025/2/2839BeijingXuanwuHospitalLaboratoryfindings
Glucose:FBG,2hrOGTT,FBGissimple,accurate,convenientforpatientGlycohemoglobinCreatinineUrinalysisglucoseketonebodiesMicroalbuminDyslipidemiaInsulinc-peptide2025/2/2840BeijingXuanwuHospitalDiabetesMellitusdefinitiontypessymptomsdiagnosisLaboratoryfindingstreatmentcomplications2025/2/2841BeijingXuanwuHospitalTreatmentofDiabetesNonPharmacologicalExerciseandEducationDiet,Lowinfat,lowrefinedsugars,highcarbohydrate,highfibre,lowcaloriesifobese,spacingofmeals(Healthyeating)LowcholesterolandtriglyceridedietifhyperlipidemiaAllType1patientswillrequireInsulinandtype2canbeondietonly,tabletsorinsulintreated2025/2/2842BeijingXuanwuHospitalTreatmentofdiabetestype1type2GDMdiet,exercise&insulindiet,exercisemetforminorsulphonylureaalonemetforminandsulphonylureametformin,sulphonylurea&thiazolidinedioneinsulindietinsulin2025/2/2843BeijingXuanwuHospitalDrugstotreathyperglycaemiaInsulinandinsulinanaloguesInsulinsecretagoguessulphonylureanon-sulphonylureaInsulinsensitizersbiguanidethiazolidinedioneIntestinalabsorptioninhibitorsacarboseorlistatlisproinsulinaspartinsulininsulinglarginegliclazide,glibenclamiderepaglinide,nateglinidemetforminrosiglitazone,pioglitazone2025/2/2844BeijingXuanwuHospitalsulphonylureaagentsgliclazide,glibenclamide,glimepiridebindtoreceptorsonisletcellsincreaseinsulinsecretionfromisletcellslongdurationofaction12-48hours
AdverseffectincreaseweightcancausehypoglycaemiacancauserashesContraindicationssulfaallergytype1DM,DKA2025/2/2845BeijingXuanwuHospitalMeglitinides
Mechanism:Bindstositeonbeta-cellmembraneleadingtoinsulinreleaseRapidoralabsorptionandeliminationforuseincontrollingpost-prandialhyperglycemia.Examples:repaglinide,nateglinideContraindicationsType1DM,DKAAdverseeffects:Hypoglycemia,weightgain2025/2/2846BeijingXuanwuHospitalmetforminlowersliverglucoseoutputincreasestissueglucoseuptakeactslikeaninsulinsensitizermildinductionofnauseapossibleinterferencewithfoodabsorptionnoeffectonweightusedalonedoesnotcausehypoglycaemiareducesriskofmyocardialinfarction1/3patientsgetdiarrhoea,windorabdominalpainnotusedinrenalfailure,heartfailureorsevereintercurrentillness2025/2/2847BeijingXuanwuHospitalMetforminToxicityRenallyexcreted,notmetabolizedPotentiallyfatallacticacidosisContraindications:renalinsufficiency(decreasesdrugclearance)hepaticdysfunction(decreaseslactatemetabolism)tissueanoxia(increaselactateproduction)2025/2/2848BeijingXuanwuHospitalacarbose-glucosidaseinhibitorblocksdigestionandabsorptionofsugarsfrombowellowersbloodglucoseandinsulinlevelsaftermealsweakantidiabeticdrugnoeffectonweightusedalonedoesnotcausehypoglycaemianotabsorbedintobody1/2patientsgetdiarrhoea,windorabdominalpain2025/2/2849BeijingXuanwuHospitala-glucosidaseinhibitortoxicityUnabsorbedCHO’s:Bacterialfermentationincolonresultsinabdominalpain,flatulencefromgasOsmoticdiarrheaElevatedserumtransaminasesMetabolizedandexcretedintheGItractSomemetaboliteisabsorbedinGIandrenallyexcretedContraindicatedforpatient’swithchronicorinflammatoryboweldiseaseRelativelyweakantidiabeticeffect,usuallyusedadjunctively.2025/2/2850BeijingXuanwuHospitalthiazolidinedioneagents
rosiglitazone,pioglitazone
Mechanism—BindtoPPAR-gammareceptorinperipheraltissuesmainlyskeletalmuscleResultinexpressionofcell-surfaceglucosetransporters.CautionsNotrecommendedinNYHAClassIII/IVCHFMaycausefluidretentionandprecipitateCHFMaycausemildanemia(?Dilutionaleffect)2025/2/2851BeijingXuanwuHospitalthiazolidinedioneagentsAssociatedwithweightgainLivertoxicityseeninolderTZD(troglitazone)butnotwithneweragents;recommendedtocheckLFTsq2mofor1styearofuse.AdvantagesNohypoglycemiaPossibleimprovementinvascularfunction2025/2/2852BeijingXuanwuHospitalThiazolidinedionetoxicityMetabolism:hepaticconjugationbytheCYP450systemExcretion:biliaryHepatotoxic,especiallytroglitazone,andcontraindicatedincasesofhepaticdysfunctionCancauseedemaandhypoglycemiawhenusedincombinationwithotherhypoglycemics2025/2/2853BeijingXuanwuHospitalTreatinghyperglycaemiaintype2diabetesdietarychangeexerciseobese
metforminnotobese
sulphonylureametformin&sulphonylureaglitazone&metforminOR
glitazone&sulphonylureainsulin±metforminAim:HbA1c<6.5%
Fastingglucose<7mmol/l2025/2/2854BeijingXuanwuHospitalinsulinanditsanaloguestheonlytreatmentfortype1diabetesalsousedfortype2diabetesandGDMcancausehypoglycaemiacausesweightgaincancausefluidretention2025/2/2855BeijingXuanwuHospitalThreemainprofiles:humanbio-engineered,porkorBovine.Variousregimens:twicedailysolubleandisophane,thricedailysoluble(pre-meal)andeveningisophane,rarelyoncedaily2025/2/2856BeijingXuanwuHospital2025/2/2857BeijingXuanwuHospitalBasal
bolusIntermediateNormalLong30:70mix2025/2/2858BeijingXuanwuHospitalRecommendedTreatment1stline:Dietandexercise2ndlineoralhypoglycemicmonotherapy(glyburide)adjunctiveto1stlinetreatmentSecond,third,andevenafourthclassofhypoglycemicscanactsynergisticallyformorediresituationsWhenallelsefails,backtotheneedle-insulintherapy2025/2/2859BeijingXuanwuHospitalEarlyAMHyperglycemia—PossibleCausesDawnphenomenonRiseinBGinearlymorningastheresultofpulsatilereleaseofinsulincounter-regulatoryhormones(growthhormoneandcortisol)SomogyiphenomenonPeriodofmorninghyperglycemiafollowingnocturnalhypoglycemia.Studieshavefailedtoshowthatthisoccurscommonly.NPHinsulingivenatdinnerwithwaningeffectbyAMLatenightsnacking2025/2/2860BeijingXuanwuHospitalDiabetesMellitusdefinitiontypesPrevalencesymptomsdiagnosistreatmentcomplications2025/2/2861BeijingXuanwuHospitalDiabeticComplicationsAcuteComplication:
hypoglycaemia,ketoacidosisoftenwithcoma(DKA), Hyperosmolarstateoftenwithcoma(HONK)Microvascularcomplications
Diabeticretinopathy,nephropathyandneuropathyMacrovascularcomplication
cerebrovascularaccidents,coronaryarterydisease,hypertension,peripheralvasculardiseasePregnancywithincreasedmaternalandfoetalmorbidity2025/2/2862BeijingXuanwuHospitalVascularcomplicationsofdiabetesretinopathynephropathyneuropathycoronaryarterydiseasecerebrovasculardiseaseperipheralvasculardisease2025/2/2863BeijingXuanwuHospitalDiabeticretinopathyleadingcauseofblindness95%ofdiabeticsubjectsshowsome
by15yearsafteronsetriskfactors:
age
diabetesduration
highbloodglucoselevels
highbloodpressure
geneticsmayprogressrapidlyduringpregnancy2025/2/2864BeijingXuanwuHospitalDiabeticretinopathyCataractformation(glycationα-crystallin)RetinopathyNonproliferative>microaneurysms>edemaProliferative(VEGF)>Newbloodvesselsthatextendintovitreous,bleeding>lossofvisionGlaucoma,intraocularpressure>oculartissuedamage2025/2/2865BeijingXuanwuHospitalNon-proliferativediabeticretinopathy(NPDR)EarlieststageMicroaneurismsandintraretinal“dotandblot〞hemorrhagesMacularedemaorhardexudatesat/nearmaculacancausevisualimpairmentProliferativediabeticretinopathy(PDR)Nonperfusionofretinaangiogenesisgrowthofabnormalnewvesselsextendingontoinnersurfaceofretinaorintovitreouscavity.Substantialriskforrupturehemorrhageorretinaldetachment.Treatedwithpanretinalphotcoagulation.2025/2/2866BeijingXuanwuHospitalDiabeticnephropathyAffects25%oftype1andtype2diabetespatientsRiskfactorssimilartothoseforretinopathyIsaprogressiveconditionleadingtorenalfailureCharacterisedbyproteinuriaandhighbloodpressure2025/2/2867BeijingXuanwuHospitalDiabeticnephropathyGlomerulosclerosis(Capillarybasementmembr.thickening)Microalbuminuria(30-300mg/24hr)Hyperfiltration(^GFR)Albuminuria(>300mg/24hr)HypertensionNephroticsyndrome(approx1/3ofType1progresstoendstagerenaldisrequiringdialysis)Renalfailure(
GFR,
Creat)2025/2/2868BeijingXuanwuHospitalDiabeticneuropathy
TypesofNeuropathySensoryPain/paresthesiasinfeetparticularlyatnightNumbnessin“stockingandglove〞distributionHighriskforfootulcerationAutonomicCardiovascular:restingtachycardia,painlessMI,orthostasisGI:esphagealdysfunction,gastroparesis,diabeticdiarrhea,constipation,fecalincontinenceGenitourinaryED,retrogradeejaculation,neurogenicbladderOther“gustatory〞sweating,heatintolerance2025/2/2869BeijingXuanwuHospitalDiabeticneuropathyAffectstype1andtype2diabetespatientssimilarlyRiskfactorssimilartothoseforretinopathymayleadtolossofsensationinfeetfootulcerationerectiledysfunctiongastroparesisandvomitingposturalhypotension2025/2/2870BeijingXuanwuHospitalMACROVASCULARCOMPLICATIONSMacrovascular(>70%hosp/deaths)60%ofpatientsdieofcoronarydisease10%ofpatientsdieofstroke10%sufferfromfatalcomplicationsrelatedtoperipheralvasculardisease2025/2/2871BeijingXuanwuHospitalCADAnginaMISilentinfarctCCFECGCardiacenzymesTroponinIExercisestresstestEchocardiographyAngiographyAngioplasty/CABG2025/2/2872BeijingXuanwuHospitalCVDTIAsCVAsDementiaCTscanCarotidDopplersTreatriskfactorsCarotidbypasssurgery2025/2/2873BeijingXuanwuHospitalPVDIntermittentClaudicationColdLegsPulselessLegFootUlcersGangreneDopplerStudiesDuplexScanningAngiographyAngioplastyTreatriskfactors2025/2/2874BeijingXuanwuHospitalDiabeticFootNeuropathyPVDCharcotArthropathyUlcerationMRIAngiography2025/2/2875BeijingXuanwuHospitalDiabeticKetoacidosisAcute(severaldaysratherthanhours)CausedbyInadequateinsulinInfectionStressUnderdosingFoodoralcoholbingeResultsinhyperglycemia&mobilizationoflipids2025/2/2876BeijingXuanwuHospitalDiabeticKetoacidosis(DKA)Type1Diabetics,SevereInsulinDef.Breakdownoffatstores>^FattyAcidsOxidation>KetoneBodies(^byglucagon)AccumulofAcetoaceticacid/βhydroxybutyricacid>^Plasma[H]>MetabolicKetoacidosis(Hydrationvsdehydration)2025/2/2877BeijingXuanwuHospitalDiabeticKetoacidosis(DKA)DKAresultsinalteredlipidmetabolismincreasedconcentrationsoftotallipids,cholesterol,triglycerides,andfreefattyacidsfreefattyacidsareshuntedintoketonebodyformationduetolackofinsulin;therateofformationexceedsthecapacityfortheirperipheralutilizationandrenalexcretionleadingtoaccumulationofketoacids,andthereforemetabolicacidosisWithprogressivedehydration,acidosis,hyperosmolality,anddiminishedcerebraloxygenutilization,consciousnessbecomesimpaired,andthepatientultimatelybecomescomatose2025/2/2878BeijingXuanwuHospitalClinicalManifestationsearlymanifestationsaremildandincludevomiting,polyuria,anddehydrationMoreseverecasesincludeKussmaulrespirations,odorofacetoneonthebreathabdominalpainorrigiditymaybepresentandmimicacuteappendicitisorpancreatitiscerebralobtundationandcomaultimatelyensue2025/2/2879BeijingXuanwuHospitalLaboratoryfindingsLaboratoryfindingsincludeglucosuria,ketonuria,hyperglycemia,ketonemia,andmetabolicacidosis.Serumamylasemaybeelevated.Leukocytosisiscommon2025/2/2880BeijingXuanwuHospitalDiagnosisDKAexistswhenthereishyperglycemia(>300mg/dL),ketonemia,acidosis,glucosuria,andketonuria2025/2/2881BeijingXuanwuHospitalDKAmustbedifferentiatedfromacidosisandcomaduetoothercauses:hypoglycemia,uremia,gastroenteritiswithmetabolicacidosis,lacticacidosis,salicylateintoxication,encephalitis2025/2/2882BeijingXuanwuHospitalTreatmentTreatmentisdividedinto3phasestreatmentofketoacidosistransitionperiodcontinuingphaseandguidanceGoalsoftreatmentofDKAintravascularvolumeexpansioncorrectionofdeficitsinfluids,electrolytes,andacid-basestatusinitiationofinsulintherapytocorrectcatabolism,acidosis2025/2/2883BeijingXuanwuHospitalKetoacidosisTreatmentAdministerinsulinRehydrateReplaceelectrolytesTreatacidosiswithbicarbonate2025/2/2884BeijingXuanwuHospitalIntravascularvolumeexpansiondehydrationismostcommonlyintheorderof10%initialhydratingfluidshouldbeisotonicsalinethisalonewilloftenslightlylowerthebloodglucoseTreatmentofelectrolyteabnormalitiesserumK+isoftenelevated,thoughtotalbodyK+isdepletedK+isstartedearlyasresolutionofacidosisandtheadministrationofinsulinwillcauseadecreaseinserumK+2025/2/2885BeijingXuanwuHospital“Maintenance〞IVfluidatarateof2000-2400cc/m2/dayconsistsof2/3NS(0.66%)orNSNSisaddedtoIVFwhenbloodglucoseis~250mg/dL5%Dextroseor5%GNSisaddedwhenbloodglucoseis~250mg/dL2025/2/2886BeijingXuanwuHospitalInsulinTherapycontinuousinfusionoflow-doseinsulinIV(~0.1U/kg/hr)iseffective,simple,andphysiologicallysoundgoalisto
slowlydecreaseserumglucose(<100mg/dL/hrfrequentlaboratoryandbloodgasanalysesareobtainedtoensureongoingresolutionofmetabolicacidosisInsulinisusedtotreatacidosis,nothyperglycemiainsulinshouldneverbestoppedifongoingacidosispersistsWhentheacidosisiscorrected,thecontinuousinsulininfusionmaybediscontinuedandsubcutaneousinsulininitiatedWiththeregimen,DKAusuallyisusuallyfullycorrectedin36to48hours2025/2/2887BeijingXuanwuHospitalsubclinicalcerebraledemaoccursinthemajorityofpatientstreatedwithfluidsandinsulinforDKACerebraledemaisthemajorlife-threateningcomplicationseeninthetreatmen
温馨提示
- 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
- 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
- 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
- 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
- 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
- 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
- 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。
最新文档
- 二零二五年度解除双方影视制作合作合同
- 2025年度科幻电影总导演专业聘用合同
- 二零二五年度电子商务平台软件使用及推广许可协议
- 2025年度生态果园产权及种植技术引进合同
- 2025年度纺织品普通采购合同书
- 二零二五年度医疗健康行业业务员委托合同
- 二零二五年度手农机售后服务与技术支持合同
- 2025年度环保项目投资欠款付款协商协议书
- 二零二五年度民间借贷合同-跨境电商供应链融资
- 二零二五年度员工股权激励与股权锁定期协议
- 托物言志写诗 知行合一做人
- 化工分离过程1绪论第1讲ppt课件精选
- 陶板幕墙施工方法
- 设备管理培训教材
- 财务报表分析财务报表分析课件
- T∕CCCMHPIE 1.2-2016 植物提取物 槟榔多糖多酚
- 局域网规划设计_毕业论文
- 胫骨平台骨折(课堂PPT)
- 冷室压铸机电脑操作控制部分操作说明
- 中考复习复分解反应类型方程式书写训练题(无答案)
- 病理学课程标准
评论
0/150
提交评论